Show simple item record

Files in this item


Item metadata

dc.contributor.authorBoyne, Caitlin
dc.contributor.authorLennox, Debra
dc.contributor.authorBeech, Olivia
dc.contributor.authorPowis, Simon J.
dc.contributor.authorKumar, Pankaj
dc.identifier.citationBoyne , C , Lennox , D , Beech , O , Powis , S J & Kumar , P 2021 , ' What is the role of HLA-I on cancer derived extracellular vesicles? Defining the challenges in characterisation and potential uses of this ligandome ' , International Journal of Molecular Sciences , vol. 22 , no. 24 , e13554 .
dc.identifier.otherJisc: 32946ae59a5147f788e7361c9b2a64a5
dc.identifier.otherORCID: /0000-0003-4218-2984/work/105318111
dc.description.abstractThe Human Leukocyte Antigen class I (HLA-I) system is an essential part of the immune system that is fundamental to the successful activation of cytotoxic lymphocytes, and an effective subsequent immune attack against both pathogen-infected and cancer cells. The importance of cytotoxic T cell activity and ability to detect foreign cancer-related antigenic peptides has recently been highlighted by the successful application of monoclonal antibody-based checkpoint inhibitors as novel immune therapies. Thus, there is an increased interest in fully characterising the repertoire of peptides that are being presented to cytotoxic CD8+ T cells by cancer cells. However, HLA-I is also known to be present on the surface of extracellular vesicles, which are released by most if not all cancer cells. Whilst the peptide ligandome presented by cell surface HLA class I molecules on cancer cells has been studied extensively, the ligandome of extracellular vesicles remains relatively poorly defined. Here, we will describe the current understanding of the HLA-I peptide ligandome and its role on cancer-derived extracellular vesicles, and evaluate the aspects of the system that have the potential to advance immune-based therapeutic approaches for the effective treatment of cancer.
dc.relation.ispartofInternational Journal of Molecular Sciencesen
dc.subjectExtracellular vesiclesen
dc.subjectAntigen presentationen
dc.subjectMass spectrometryen
dc.subjectCancer immunologyen
dc.subjectQH301 Biologyen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleWhat is the role of HLA-I on cancer derived extracellular vesicles? Defining the challenges in characterisation and potential uses of this ligandomeen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Cellular Medicine Divisionen
dc.contributor.institutionUniversity of St Andrews. Centre for Biophotonicsen
dc.contributor.institutionUniversity of St Andrews. Biomedical Sciences Research Complexen
dc.contributor.institutionUniversity of St Andrews. St Andrews Bioinformatics Uniten
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record